Malaysia Launches First-Ever "Medical Tourism Year" — Can It Outcompete China?

What Is MYMT 2026?

MYMT 2026 officially launched at the Malaysia International Trade and Exhibition Centre in Kuala Lumpur. It is the Malaysia Healthcare Travel Council's first dedicated "Year of Medical Tourism" campaign, running alongside Visit Malaysia 2026. Health Minister Datuk Seri Dr Dzulkefly Ahmad called it a full-court press to push Malaysia into the upper echelon of global healthcare destinations.

The campaign tagline emphasizes "excellent medical care delivered with cultural sensitivity, warmth, and a deep commitment to patient well-being." It covers fertility treatments, cardiac care, wellness retreats, and executive health screenings.

Why Now?

Malaysia is pushing hard in 2026 for several reasons. The 2024 numbers were solid — 1.6 million healthcare travelers and RM2.72 billion in revenue, up 21% from the previous year, so the momentum is there. But regional competition has intensified. Thailand has been dominant for years; Singapore has pivoted toward premium tech-driven care; and China has entered the market with Hainan's Boao Lecheng zone posting 109% growth. Malaysia also lost some ground during the pandemic recovery period and is now trying to reclaim position rather than build from scratch.

The MYMT campaign aims to change that through coordinated international marketing, new healthcare travel packages with airline and hotel partners, and a push to get more private hospitals JCI-accredited.

What Malaysia Does Well

Malaysia's healthcare system has genuine strengths. The country has long been known for affordable, quality care — particularly in fertility treatment, cardiology, and orthopedics. Hospitals in Kuala Lumpur and Penang have accumulated decades of experience treating international patients, and the medical visa process is relatively smooth for key source markets.

Malaysia pitches itself as a destination where patients are treated as guests, not cases. Food, language accessibility, and hospitality infrastructure all reinforce that. For patients from Indonesia, the Middle East, and parts of Southeast Asia, Malaysia has long felt like a natural choice.

China's Growing Medical Tourism Sector

China is not standing still. The Boao Lecheng zone in Hainan received 865,460 visitors in 2025 — more than double the previous year — and is targeting 2.5 million by 2027. China's pitch is different: it emphasizes advanced oncology (CAR-T therapy, proton beam, heavy ion radiation), access to treatments not yet approved in other markets, and a regulatory fast-track pathway that can get patients treated with drugs or devices that are still pending approval elsewhere.

China is also aggressively recruiting international patients through the CMTF (China International Medical Tourism Fair) and offers visa-free entry for citizens of a growing list of countries.

Malaysia vs China: How They Compare

Here is how the two destinations stack up heading into mid-2026:

Challenges for Malaysia

MYMT 2026 is ambitious, but Malaysia faces real hurdles. The country's strongest medical tourism infrastructure is concentrated in Kuala Lumpur and Penang, so most international patients are funneled into two cities. Malaysia also lacks the regulatory innovation that makes Hainan attractive — it cannot offer fast-track access to experimental treatments the way the Boao Lecheng zone can.

The currency has also strengthened against many regional currencies, making Malaysia more expensive relative to Thailand and Indonesia for cost-sensitive patients. That has been a headwind for Singapore too, which is why Singapore pivoted toward premium and technology-driven care rather than competing on price.

What This Means for Patients

More competition in medical tourism is good news for patients. Malaysia's MYMT 2026 is likely to bring promotional pricing, improved service packages, and better coordination between hospitals and travel providers. China's continued investment in Boao Lecheng and international patient programs gives patients another option for advanced treatments — particularly those not yet available at home.

The broader trend is clear: Asia's medical tourism market is fragmenting into distinct niches rather than consolidating around one or two dominant hubs. Thailand still leads in cosmetic surgery and general wellness. Singapore leads in high-complexity, technology-intensive care. Malaysia is fighting for the fertility, cardiac, and affordable advanced care segment. China is carving out a position in experimental oncology and TCM-integrated treatment. Patients who do their homework have more genuine options than ever before.